BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...

Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

According to preliminary data, the S&P 500 lost 16.58 points, or 0.28%, to end at 6,051.92 points, while the Nasdaq Composite ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

Salesforce has announced a new CFO+ with an expanded set of responsibilities as a company veteran who "bleeds CRM" prepares ...

California Democratic Rep. Jared Hoffman protested the National Prayer Breakfast Thursday, claiming it violates the separation between church and state. The congressman said in an X video […] ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims ...

(KOA), the largest system of privately owned campgrounds in the world, is proud to announce that Mt. Gilead KOA Holiday has ...

Ivanka Trump wore a timeless remake of a Givenchy dress at tonight's inauguration ball after sporting a green ensemble ahead of the inauguration which reminded some of a dystopian story ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...